ENTITY

Tiziana Life Sciences (TILS LN)

2
Analysis
Health CareUnited Kingdom
Tiziana Life Sciences plc, a clinical stage biotechnology company, focuses on the discovery and development of novel therapeutics for cancer in the United Kingdom. The company?s product candidate includes Milciclib that is in phase II clinical trials for thymic carcinoma in patients previously treated with chemotherapy. It also develops Foralumab, a human anti-CD3 antibody, which is in phase II clinical stage for autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis; and Bcl-3 for use in metastasis of mammary cancers. The company is based in London, the United Kingdom. Tiziana Life Sciences plc is a subsidiary of Planwise Group Limited.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x